<DOC>
	<DOCNO>NCT02606617</DOCNO>
	<brief_summary>With improvement live level , incidence rate diabetes , obesity , hypertension China increase quickly , 11.6 % , 7.1 % 18.8 % respectively , accord newly investigate data . The clustering diabetes , obesity , hypertension dyslipidemia increase risk cardiovascular event patient . GLP-1 ( glucagon like peptide-1 ) kind incretin discover recent year . It report beside hypoglycemic losing weight effect , activator GLP-1 receptor could decrease blood pressure improve lipid metabolism . Sleeve gastrectomy improve level blood glucose serum lipid type 2 diabetic rat ameliorate insulin level insulin resistance , may relate change gastrointestinal hormone ghrelin GLP-1 . So , intervention gastrointestinal tract gastrointestinal hormone secretion may new therapy glycolipids disorder vascular complication . But , lack evidence-based medicine proof relationship prokinetic drug glycolipids metabolism . So , investigator design prospective , randomize , double-blinded , placebo control study , try evaluate effect prokinetic drug ( Mosapride ) blood glucose serum lipid type 2 diabetic patient .</brief_summary>
	<brief_title>A Clinical Trial Analyzing Effects Prokinetic Drug Blood Glucose Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<criteria>Male female , age 3065 year old Type 2 diabetes Duration diabetes less 5 year pancreatic function compensate stage . 7 % ≤HbA1C≤9 % Patients able control diet exercise intervention period . Type 2 diabetes serious complication , diabetic neuropathy , diabetic retinopathy , stage IV diabetic nephropathy , acute diabetic complication . Type 2 diabetes use insulin , GLP1 analogues DPPIV inhibitor ) . Heart function NYHA Grade IIIV history cardiocerebral vascular event congestive heart failure , myocardial infarction stroke within 3 month . Hypohepatia ( AST ALT two time higher upper limit ) history cirrhosis , hepatic encephalopathy , esophageal varix portal shunt . Renal insufficiency ( serum creatinine 1.5 time high upper limit ) history dialysis nephritic syndrome . Chronic obstructive pulmonary disease ( COPD ) , chronic respiratory failure hyoxemia . Acute infection , tumor , severe arrhythmia , mental disorder , alcohol medicine addiction . Fertile woman without contraceptive . Any surgical medical condition significantly influence absorption , distribution , metabolism excretion intervention drug . Allergic contraindication intervention drug .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Mosapride</keyword>
	<keyword>blood glucose</keyword>
	<keyword>serum lipid</keyword>
</DOC>